EGFR and non-small cell lung carcinoma: A Japanese retrospective study (n = 27) of PD-1 inhibitors concluded that NSCLC patients with uncommon EGFR mutations and without T790M mutations exhibited significantly longer PFS than patients with common mutations or T790M mutations in EGFR [105].